Brokers Set Expectations for NEUP Q2 Earnings

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Neuphoria Therapeutics Inc. – Common Stock in a research note issued on Tuesday, February 4th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($2.01) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.85) EPS.

Neuphoria Therapeutics Inc. – Common Stock Price Performance

Neuphoria Therapeutics Inc. – Common Stock stock opened at $5.04 on Thursday. Neuphoria Therapeutics Inc. – Common Stock has a 1 year low of $2.12 and a 1 year high of $16.08.

About Neuphoria Therapeutics Inc. – Common Stock

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.